Bon comme tu n’es pas capable de le faire je vais faire le travail, je vais t’expliquer
Mitja, conclusion : In patients with mild COVID-19, no benefit was observed with HCQ beyond the usual care.
les premières lignes de l’étude Mitja :
For positive symptomatic cases, a greater effect is seen for nursing
home residents, RR=0.49 [0.21 - 1.17], vs. overall 0.89, possibly
because the exposure events are identified faster in this context,
versus home exposure where testing of the source may be more delayed.
The trial is too small for significance here. If the trend continued
this result would be significant at p<0.05 after about 25% more patients were added.
Conclusion :
risk of death, 45.6% lower, RR 0.54, p = 0.39,
treatment 4 of 1,196 (0.3%), control 8 of 1,301 (0.6%), NNT 357, per
supplemental appendix table S7, excluding patient that did not take any
study medication and had an unknown cause of death.
risk of hospitalization, 16.8% lower, RR 0.83, p = 0.71,
treatment 13 of 1,196 (1.1%), control 17 of 1,301 (1.3%), NNT 455, per
supplemental appendix table S7, excluding patient that did not take any
study medication and had an unknown cause of death.
baseline PCR- risk of cases, 32.0% lower, RR 0.68, p = 0.27, treatment 29 of 958 (3.0%), control 45 of 1,042 (4.3%), NNT 77.